Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes.A3290, A259053 Egaptivon pegol is a therapeutic oligonucleotide ("aptamer") which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, thereby modulating platelet adhesion, activation, and aggregation under the high shear conditions of coronary arterial stenosis and plaque rupture.A3290
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Peginterferon alfa-2a | The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Peginterferon alfa-2a. |
| Pegfilgrastim | The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Pegfilgrastim. |
| Peginterferon alfa-2b | The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Peginterferon alfa-2b. |
| Pegaspargase | The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Pegaspargase. |
| Pegademase | The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Pegademase. |
| Pegvisomant | The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Pegvisomant. |
| Propylene glycol | The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Propylene glycol. |
| Heptaethylene glycol | The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Heptaethylene glycol. |
| Pegaptanib | The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Pegaptanib. |
| PEG-uricase | The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Egaptivon pegol. |
| Peginterferon alfacon-1 | The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with Egaptivon pegol. |
| GlycoPEG-GCSF | The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Egaptivon pegol. |
| Pegnivacogin | The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Egaptivon pegol. |
| Pegpleranib | The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Egaptivon pegol. |
| Pegsunercept | The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Egaptivon pegol. |
| Polidocanol | The therapeutic efficacy of Polidocanol can be decreased when used in combination with Egaptivon pegol. |
| Peginesatide | The therapeutic efficacy of Peginesatide can be decreased when used in combination with Egaptivon pegol. |
| Certolizumab pegol | The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Egaptivon pegol. |
| Methoxy polyethylene glycol-epoetin beta | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Egaptivon pegol. |
| Peginterferon beta-1a | The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Egaptivon pegol. |
| Pegloticase | The therapeutic efficacy of Pegloticase can be decreased when used in combination with Egaptivon pegol. |
| Polyethylene glycol | The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Egaptivon pegol. |
| Antihemophilic factor (recombinant), PEGylated | The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Egaptivon pegol. |
| Insulin peglispro | The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Egaptivon pegol. |
| Eptacog alfa pegol (activated) | The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Egaptivon pegol. |
| Olaptesed Pegol | The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Egaptivon pegol. |
| Abicipar Pegol | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Egaptivon pegol. |
| Lexaptepid pegol | The therapeutic efficacy of Lexaptepid pegol can be decreased when used in combination with Egaptivon pegol. |
| Cepeginterferon alfa-2B | The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Egaptivon pegol. |
| Pegvaliase | The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Egaptivon pegol. |
| Pegamotecan | The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Egaptivon pegol. |
| Lipegfilgrastim | The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Egaptivon pegol. |
| Nonacog beta pegol | The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Egaptivon pegol. |
| Damoctocog alfa pegol | The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Egaptivon pegol. |
| Elapegademase | The therapeutic efficacy of Elapegademase can be decreased when used in combination with Egaptivon pegol. |
| Rurioctocog alfa pegol | The therapeutic efficacy of Rurioctocog alfa pegol can be decreased when used in combination with Egaptivon pegol. |